VIVO News and Press, Meridian Bioscience Inc. From 02/05/21

Image source: The Motley Fool. Meridian Bioscience Inc (NASDAQ: VIVO) Q1 2021 Earnings Call Feb 5, 2021 , 10:00 a.m. ET Operator Continue reading For further details see: Meridian Bioscience Inc (VIVO) Q1 2021 Earnings Call Transcript

Meridian Bioscience, Inc. (VIVO) Q1 2021 Earnings Conference Call February 05, 2021, 10:00 ET Company Participants Charles Wood - VP, Corporate Strategy, Business Development & IR John Kenny - President, CEO & Director Bryan Baldasare - EVP, CAO, CFO & Secretary Conference Call Pa...

Meridian Bioscience (VIVO): Q1 Non-GAAP EPS of $0.66 beats by $0.24; GAAP EPS of $0.62 beats by $0.20.Revenue of $92.9M (+95.9% Y/Y) beats by $4.57M.Press Release For further details see: Meridian Bioscience EPS beats by $0.24, beats on revenue

CINCINNATI, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2020. First Quarter 2021 Highlights (Comparison to First Quarter Fiscal 2020): Consolidated net revenues of $92.9...

High-scoring, high short-interest stocks that can benefit from ongoing short covering by hedge funds as they reduce single stock risk. Institutional quality stocks with potential catalysts that support ongoing short covering, rather than flash-in-the-pan volatility. Ideas across a...

Meridian Bioscience ([[VIVO]] -0.7%) will increase production capacity of the company's SARS-CoV-2 molecular diagnostic test on its Revogene platform after receiving a $5.5M award from the National Institute of Health ((NIH)) Rapid Acceleration of Diagnostics initiative and an additional...

CINCINNATI, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it will increase production capacity of the company's SARS-CoV-2 molecular diagnostic test on its Revogene ...

CINCINNATI, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has developed a series of innovative and high performing master mixes designed for manufa...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

CINCINNATI, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report first quarter fiscal 2021 financial results Friday, February 5, 2021. Jack Kenny, Chief Executive Officer, and...